A r t i c l e s of EZH2 + CD3 + T cells in tonsil, spleen and ulcerative colitic colon tissues ( Supplementary Fig. 1a) . Polychromatic flow cytometry analysis demonstrated that peripheral blood EZH2 + T cells were confined to CD45RA − CD62L − CD45RO + memory cells (Fig. 1a) . Neither EZH2 + CD4 + nor EZH2 + CD8 + T cells expressed KLRG1, Tim-3 or CD57, markers associated with T cell anergy and senescence 6, 8 ( Fig. 1b) . Thus, EZH2 + T cells are different from anergic and senescent memory T cells.
We further examined the effector cytokine profile and cytotoxic protease of EZH2 + T cells (Supplementary Fig. 1b) . EZH2 + CD4 + T cells were enriched with cells expressing two or three of the effector cytokines interleukin 2 (IL-2), interferon-γ (IFN-γ) and tumor necrosis factor (TNF) (Fig. 1c,d ). EZH2 + CD8 + T cells were enriched with cells expressing two (double positive) or three (triple positive) of the effector molecules IFN-γ, TNF and granzyme B (Fig. 1c,d ). These data indicate that a high proportion of EZH2 + T cells express multiple effector cytokines (i.e., are polyfunctional) (Supplementary Fig. 1b) .
Polychromatic flow cytometry analysis also detected EZH2 + CD8 + T cells in human ovarian cancer tissue. Ovarian cancer-infiltrating EZH2 + CD8 + T cells were phenotypically distinct from KLRG1 + CD8 + T cells, Tim-3 + CD8 + T cells and CD57 + CD8 + T cells (Fig. 1e) . Ovarian cancer-infiltrating EZH2 + CD8 + T cells were also enriched with polyfunctional T cells (Fig. 1f) . TUNEL assay showed that there were fewer spontaneously apoptotic T cells in EZH2 + T cells than in EZH2 − T cells in ovarian cancer tissues (Fig. 1g) . Consistent with the antiapoptotic role of Bcl-2 in human effector T cells 18, 19 , we observed that polyfunctional T cells and EZH2 + T cells expressed high amounts of Bcl-2 ( Fig. 1h,i) . These data suggest that EZH2 + T cells may have a survival advantage. To further explore this possibility, we examined T cell survival in the presence of cisplatin, a first-line chemotherapeutic agent for ovarian cancer. Cisplatin induced CD8 + T cell apoptosis ( Supplementary Fig. 1c ) and increased the percentage of polyfunctional CD8 + T cells, as compared to cells cultured without cisplatin. Cisplatin treatment did not affect the absolute numbers of polyfunctional CD8 + T cells (Fig. 1j) . These data indicate that polyfunctional CD8 + T cells are relatively resistant to cisplatin-induced apoptosis. Consistent with this observation, EZH2 expression was higher in CD8 + T cells treated with cisplatin than in untreated cells (Supplementary Fig. 1d ). EZH2 + CD8 + T cells were enriched with polyfunctional T cells (Fig. 1f) and were less susceptible to spontaneous ( Fig. 1g) and chemotherapy-induced (Fig. 1j ) apoptosis than were EZH2 − T cells in the human ovarian cancer microenvironment. Thus, EZH2 + T cells may be functional effector T cells in the tumor microenvironment and may mediate potent antitumor immunity. However, the ratios between the percentage of EZH2 + CD8 + effector T cells and that of dysfunctional T cells (KLRG1 + , Tim-3 + or CD57 + ) were lower in ovarian cancer than in peripheral blood ( Fig. 1k-m) and noncancerous ovary cysts (Fig. 1n-p) . The imbalance between functional effector T cells and dysfunctional T cells suggests a loss of polyfunctional effector T cells in the cancer microenvironment.
EZH2 regulates effector T cell polyfunctionality and survival
Given that EZH2 expression coincided in polyfunctional and apoptosisresistant effector T cells, we hypothesized that EZH2 may functionally regulate T cell polyfunctional cytokine profile and survival. To test this hypothesis, we activated T cells with antibodies to CD3 (anti-CD3) and anti-CD28. We observed an increase (as compared to freshly isolated T cells) in expression of EZH2 and H3K27me3 upon T cell activation ( Fig. 2a and Supplementary Fig. 2a) . Notably, biochemical inhibition of EZH2 expression with the histone methyltransferase inhibitor DZNep 20 resulted in fewer CD8 + T cells with double-or triple-positive expression of IFN-γ, TNF and granzyme B, as compared to untreated cells (Fig. 2b,c) . To confirm these results, we knocked down EZH2 expression with EZH2-specific short hairpin RNA (shEZH2). As expected, shEZH2 caused reduced expression of EZH2 and H3K27me3 and decreased percentages of polyfunctional CD8 + T cells, as compared to a scramble vector (Fig. 2d-f) .
To test the effect of EZH2-associated H3K27me3 on T cell polyfunctionality, we used GSK126, an EZH2-specific S-adenosylmethioninecompetitive inhibitor compound 21 . T cells treated with GSK126 showed complete loss of EZH2-associated H3K27me3 without any change in EZH2 protein abundance (Fig. 2g) . GSK126 treatment inhibited polyfunctionality, as shown by reduced percentages of double-and triple-positive CD8 + T cells (Fig. 2h,i) . These data indicate that EZH2 regulates T cell polyfunctionality via EZH2-associated H3K27me3.
As EZH2 + T cells are more resistant to apoptosis, we wondered whether EZH2 is also involved in the control of effector T cell survival. Flow cytometry analysis showed that treatment with DZNep or GSK126 increased the percentage of apoptotic (annexin V + ) T cells under T cell antigen receptor (TCR) engagement (Fig. 2j) . Similarly, shEZH2 treatment increased T cell apoptosis (Fig. 2j) . In further support of the nature of EZH2-mediated resistance to apoptosis, DZNep treatment lowered Bcl-2 mRNA and protein expression in T cells, as compared to untreated cells ( Supplementary Fig. 2b and Fig. 2k) . Inhibition of EZH2 promoted the expression of genes encoding the proapoptotic proteins BAK, BAX and BIM in T cells ( Supplementary  Fig. 2c ). T cells transduced with shEZH2 expressed less Bcl-2 than did cells treated with scrambled vector (Fig. 2l) . Furthermore, knockdown of EZH2 reduced BCL2 promoter activity (Fig. 2m) . These data indicate that EZH2 may regulate Bcl-2 expression and consequently control effector T cell survival. Thus, EZH2 is a key regulatory gene controlling effector T cell polyfunctionality and survival.
EZH2 inhibits T cell Notch repressors
We next explored how EZH2 regulates effector T cell polyfunctionality and survival. The Notch signaling pathway regulates effector T cell survival 19, 22 and effector function, including cytokine expression 23 . We hypothesized that EZH2 alters the Notch signaling pathway and in turn affects T cell cytokine profile and survival. As expected, when human T cells were activated, EZH2 and intracellular domain of Notch (NICD) were synchronically induced (Fig. 3a) . Knockdown of EZH2 with shEZH2 decreased the amount of NICD (Fig. 3b) . DZNep treatment suppressed Notch signaling activation as shown by reduced expression of HES1, HEY1 and HEY2 , which are direct targets of NOTCH (Fig. 3c) . Those data indicate that EZH2 may promote acivation of Notch signaling in T cells. EZH2 is one of the Polycomb group family members that functions in transcriptional repression 12 . We hypothesized that EZH2 targets and represses Notch repressors and consequently activates Notch. To test this hypothesis, we analyzed expression of NUMB and FBXW7, two important Notch suppressors 24, 25 , after blockade of EZH2 expression. We found that blockade with DZNep led to elevated expression of NUMB and FBXW7 in comparison to vehicle treatment (Fig. 3d) . ChIP assays revealed high occupancies of H3K27me3 in the proximal promoter areas of NUMB and FBXW7, whereas genetic knockdown of EZH2 abrogated these occupancies (Fig. 3e) . These data suggest that EZH2 targets Notch repressors and promotes Notch activation and may, consequently, regulate effector T cell polyfunctionality and survival. In line with this, we observed that Notch inhibitors DAPT and GSI-I suppressed CD8 + T cells double or triple-positive for IFN-γ, TNF and granzyme B, and increased effector npg A r t i c l e s 
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Glucose restriction impairs T cell function in tumors Polyfunctional T cells mediate antiviral immunity [1] [2] [3] [4] [5] . Many studies have focused on T cell exhaustion and senescence. However, the reason for the relative loss of EZH2 + polyfunctional T cells in the cancer microenvironment is poorly understood. To address this question, we initially examined how polyfunctional T cells were regulated in T cell apoptosis, in comparison to vehicle treatment ( Fig. 3f-h and Supplementary Fig. 3a) . Furthermore, ectopic expression of the Notch active domain (Notch-IC) increased BCL2 promoter activity ( Supplementary Fig. 3b ). These data suggest that EZH2 targets Notch repressors and promotes Notch activation, affects Bcl-2 activation and controls effector T cell polyfunctionality and survival. npg A r t i c l e s the tumor microenvironment. A switch from oxidative phosphorylation to aerobic glycolysis is crucial for T cell acquisition of effector functions 9, 10 . We hypothesized that glucose restriction in tumor tissue reduces numbers of polyfunctional T cells. To test this hypothesis, we cultured CD8 + T cells with RPMI 1640 with 10% FCS and 2 mg/ml glucose (normal medium), tumor-conditioned medium from primary ovarian cancer cells 26 , normal medium supplemented with 2 mg/ml glucose and tumor medium supplemented with 2 mg/ml glucose (Fig. 4a) . We subsequently analyzed the ability of these cells to undergo a metabolic switch and its association with polyfunctional T cells. Tumor medium contained low concentrations of glucose (Fig. 4a) .
As expected, T cells cultured in normal medium responded efficiently to TCR-engaged activation and increased extracellular acidification rate (ECAR). In contrast, CD8 + T cells cultured in tumor medium were poorly responsive to activation, as demonstrated by reduced ECAR (Fig. 4b) . Glucose supplementation partially rescued ECAR in T cells cultured with tumor medium but had no effect on ECAR in T cells cultured with normal medium (Fig. 4a,b) . We further evaluated the ratio between ECAR and oxygen consumption rate (OCR) in CD8 + T cells conditioned with ovarian cancer medium. We observed a lower ECAR/OCR ratio in tumor-conditioned T cells than in T cells conditioned in normal medium (Fig. 4c) . Accompanied with a reduced ECAR and ECAR/OCR ratio, culture with tumor medium resulted in lower numbers of polyfunctional CD8 + T cells, as shown by reduced frequencies of double-positive and triple-positive CD8 + T cells and high frequencies of apoptotic CD8 + T cells (Fig. 4d-f) .
Again, glucose supplementation reversed these effects (Fig. 4d-f) . Similar results were obtained in polyfunctional CD4 + T cells (Supplementary Fig. 4a,b) . We also cultured CD8 + T cells in normal medium containing glucose at concentrations similar to that of tumor medium (0-1 mg/ml). We found that low concentrations of glucose resulted in reduced numbers of polyfunctional CD8 + T cells (Supplementary Fig. 4c ) and a higher frequency of apoptosis (Supplementary Fig. 4d ). We also examined the influence of glucose on the expression of ligand for PD-1 (PD-L1 (B7-H1)) and B7 homolog 4 (B7-H4, B7x, B7s) in ovarian cancer cells. Glucose restriction or supplementation did not alter their expression ( Supplementary  Fig. 4e) . Furthermore, the hexokinase inhibitor 2-deoxy-d-glucose (2-DG) treatment reduced the number of polyfunctional T cells and increased the percentage of apoptotic T cells, as compared to untreated cells (Fig. 4g,h and Supplementary Fig. 4f ). Taken together, these data suggest that tumor impairs T cell glycolysis, inhibits their polyfunctionality and promotes their apoptosis.
Tumor controls T cell EZH2 via specific miRNAs Given our observations that EZH2 regulates T cell polyfunctionality and survival, tumor microenvironments impairs T cell polyfunctionality and survival via glucose restriction and T cell activation induces EZH2 expression, we hypothesized that the tumor environment controls T cell EZH2 induction via glucose restriction and, in turn, regulates T cell polyfunctionality and apoptosis. To test this hypothesis, we activated and cultured T cells in the presence of medium 
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from cultured primary ovarian cell cultures and examined their EZH2 expression. We observed that tumor medium impaired EZH2 expression in both CD4 + and CD8 + T cells (Fig. 5a,b and Supplementary  Fig. 5a ). Notably, glucose supplementation of growth medium rescued EZH2 expression (Fig. 5a,b and Supplementary Fig. 5a ). Low concentrations of glucose in fresh culture medium also caused reduced EZH2 expression (Supplementary Fig. 5b ). These data suggest that T cell EZH2 expression was impaired via glucose restriction. In line with this possibility, we observed that 2-DG strongly inhibited EZH2 expression in CD4 + and CD8 + T cells (Fig. 5c) . Thus, tumor microenvironments reduce EZH2 expression via impairment of glucose metabolism. Next, we examined how tumor cells impair EZH2 expression in T cells. The miRNAs miR-101 (ref. 27 ) and miR-26a (ref. 28 ) regulate EZH2 expression in tumor cells. In parallel to the increase in EZH2 expression, we observed a rapid reduction in abundance of miR-101 and miR-26a in the course of T cell activation, whereas many miRNAs, including miR-223, miR-106b and miR-181a were not affected (Fig. 5d,e and Supplementary Fig. 5c ). In the presence of tumor cells, however, the expression of miR-101 and miR-26a remained high and was significantly reduced by the addition of glucose, whereas supplementation of normal medium with additional glucose did not affect miRNA expression (Fig. 5f,g ). In line with this observation, miR-101 and miR-26a were more abundant in T cells cultured in normal medium supplemented with limited glucose than in T cells grown in medium containing normal glucose concentrations (2 mg/ml) (Supplementary Fig. 5d ). This observation suggests that the tumor microenvironment may promote and sustain miR-101 and miR-26a expression in T cells via glucose restriction. In further support of this, 2-DG treatment prevented the loss of miR-101 and miR-26a in T cells activated with TCR engagement (Fig. 5d-g ). As expected, transfection of T cells with miR-101 and miR-26a mimics led to the reduction of EZH2 expression, decreased the frequency of polyfunctional T cells and enhanced T cell apoptosis (Fig. 5g-j) . Accordingly, the absolute numbers of viable T cells were reduced in cells transfected with miR-101 and miR-26a mimics (Supplementary Fig. 5e ).
miR-101 (ref. 27 ) and miR-26a 28 target the gene encoding EZH2 through its 3′ untranslated region (UTR). To determine whether miR-101 and miR-26a may target other genes and regulate T cell survival and polyfunctionality, we constructed plasmid encoding EZH2 without a 3′ UTR 27 and overexpressed this construct in T cells. As expected, miR-101 and miR-26a mimics had no effect on EZH2 expression in T cells with overexpression of EZH2 without 3′ UTR (Supplementary Fig. 6a ). miR-101 and miR-26a mimics inhibited Bcl2 expression, Hey1 expression and polyfunctional CD8 + T cell formation in control T cells transfected with empty plasmid, but not in EZH2-overexpressing T cells (Supplementary Fig. 6b-d) . Thus, we propose that cancer mediates effector T cell dysfunction by targeting miRNAs, EZH2 and the Notch repressor signaling pathway via restriction of aerobic glycolysis.
EZH2 affects tumor immunity and patient survival EZH2 marks polyfunctional T cells and controls their survival. We wondered whether EZH2 might affect T cell-mediated antitumor immunity in vivo. To investigate this question, we employed a mouse model of melanoma with lung metastasis. Adoptively transferred tumor-specific T cells protected mice from lung metastasis (Fig. 6a) . Pre-treatment of T cells with DZNep inhibited the expression of EZH2 and H3K27me3 and impaired the protective role of T cells, as indicated by an increased number of tumor foci in the lung (Fig. 6a) . Similarly, EZH2 knockdown in T cells increased lung metastasis as compared to a control shRNA with a scrambled sequence (Fig. 6b) . We further examined the effects of EZH2 on T cell-mediated antitumor immunity in a humanized ovarian cancer model 19, 29 . Human ovarian cancer-specific T cells were treated with DZNep and intravenously transfused into ovarian cancer-bearing mice 19 . We observed greater tumor growth in mice that received tumor-specific T cells pretreated with DZNep in vitro than in mice that received T cells not treated with DZNep (Fig. 6c) . These results, together with our observations that EZH2 inhibition reduces T cell polyfunctionality, indicate that EZH2 controls polyfunctional T cell-mediated antitumor immunity in vivo.
The surface phenotype of tumor-infiltrating T cell subsets has been studied in human cancers 29, 30 . Given the polyfunctional profile of EZH2 + T cells, we hypothesized that tumor-infiltrating EZH2 + CD8 + T cells positively affect cancer survival. To test this hypothesis, we quantified the frequencies of EZH2 + CD8 + T cells via immunohistochemistry in tissue samples from 135 patients with ovarian cancer for whom clinical and pathological information was available (Supplementary Table 1) . On the basis of the median numbers of CD8 + T cells and EZH2 + CD8 + T cells and the percentage of EZH2 + CD8 + T cells in total CD8 + T cells, we divided patients into two groups, designated 'low' and 'high' . Univariate analysis demonstrated no significant correlations between the number of CD8 + T cells and overall patient survival (Fig. 6d and Supplementary Table 1) or between the number of CD8 + T cells and disease-free interval (Fig. 6e and Supplementary Table 1) . However, EZH2 + CD8 + T cell numbers and the percentage of EZH2 + CD8 + T cells highly correlated with improved overall survival and disease-free interval (Fig. 6f-i  and Supplementary Table 1) . Age, tumor stage and debulking and grade were important prognostic factors for overall and disease-free survival (Supplementary Table 1) . After adjusting for these clinical prognostic factors and histology, the number and percentage of EZH2 + CD8 + T cells remained significant (P < 0.05) predicators of overall and disease-free survival (Supplementary Tables 2-4) .
To estimate the accuracy of CD8 + T cell numbers, EZH2 + CD8 + T cell numbers and the percentages of EZH2 + CD8 + T cells for predicting survival, we used time-dependent receiver-operating-characteristic (ROC) curve analysis 31 . We calculated the area under the ROC curve (AUC) to evaluate the predictive accuracy of each marker for estimating long-term (10-year) survival. The AUC for CD8 + T cells was significantly lower than that for EZH2 + CD8 + cells, expressed in both number and percentage (Fig. 6j,k) . This finding indicates that expression of EZH2 in CD8 + T cells is a stronger predictor for longterm overall survival and disease-free interval than is CD8 expression alone (Fig. 6j,k) . Moreover, the percentage of EZH2 + CD8 + T cells was A r t i c l e s associated with a significantly higher AUC were the numbers of CD8 + T cells or EZH2 + CD8 + T cells, for both overall survival and disease-free interval (Fig. 6j,k) . Similar results were obtained for survival from 6-8 years. These data suggest that the percentage of EZH2 + CD8 + T cells precisely predicts outcomes and long-term survival for patients with ovarian cancer. Taken together, our results demonstrate how EZH2 marks polyfunctional T cells and controls tumor immunity and affects patient outcome.
DISCUSSION
Effector memory T cells, including polyfunctional T cells, mediate potent protective immunity in viral infection [1] [2] [3] [4] [5] . Although T cell infiltration of tumors is associated with improved patient survival [15] [16] [17] , the nature of T cell effector functions, including survival and polyfunctionality, remains poorly understood. Furthermore, memory T cell subsets are under active investigation in the context of immune vaccination, T cell therapy and inhibitory checkpoint blockade therapy 6, 19, [32] [33] [34] [35] [36] . It has been proposed that memory T cell differentiation status, survival and 'stemness' properties 19, [34] [35] [36] [37] and the percentage of CD27 + CD28 + T cells 37 may be crucial factors in determining their antitumor potency 19, [34] [35] [36] 38 . However, it is not clear which T cell subset truly mediates antitumor immunity in patients with cancer. Understanding the features of the protective T cells in cancer patients will provide significant guidance in designing T cell therapies and evaluating therapeutic efficacy of immune vaccination and therapy.
Here we have phenotypically, functionally and clinically demonstrated that EZH2 + T cells mediate potent antitumor immunity in human cancer and are associated with long-term survival. Epigenetic and chromatin remodeling may occur rapidly in activated memory T cells 9 . We found that 48 h after TCR engagement, substantial EZH2 expression was induced in T cells. EZH2 expression highly coincides in polyfunctional memory T cells. Major transcriptional factors, including T-bet, GATA-3 and RORγt control the differentiation and function of T H 1, T H 2 and T H 17 effector T cell subsets. It is unknown whether polyfunctional T cells are controlled by a major transcription factor. Although EZH2 is not known as a transcription factor, we have shown that EZH2 is involved in defining the survival and polyfunctional cytokine profile of effector T cells. To further study the mechanism by which EZH2 controls effector T cell survival and polyfunctionality, we have shown that EZH2 directly binds to the promoter areas of genes encoding Notch repressors, NUMB and FBXW7, and represses their transcription via H3K27me3 and subsequently causes Notch activation, which results in antiapoptotic gene activation and effector cytokine expression. Thus, EZH2 targets the Notch signaling pathway to regulate effector T cell polyfunctionality and survival.
Given the functional and mechanistic importance of EZH2 in polyfunctional T cells in cancer, it is essential to dissect how T cell EZH2 is controlled in the tumor microenvironment, a hypoglycemic environment owing to the Warburg effect. Notably, we have found that primary ovarian cancer cells reduce the EZH2 expression and limit polyfunctional cytokine expression and survival of effector T cells, which can subsequently be rescued by glucose supplementation and mimicked by 2-DG treatment. This observation suggests that T cell EZH2 is controlled by glycolytic metabolism in the cancer environment. In line with our observations, studies have demonstrated that glycolytic switch regulates memory T cell activation, proliferation and IFN-γ expression in mouse models 9, 10, 39 . Further mechanistic studies have shown that tumor cells sustain high expression of miR-26a and miR-101 in effector T cells. Consequently, these miRNAs lessen EZH2 expression and cause effector T cell dysfunction. Thus, our data reveal a metabolic target and mechanism of cancer immune evasion: cancer restricts T cell EZH2 expression by limiting their aerobic glycolysis and consequently weakens T cell-mediated antitumor immunity.
This study has notable clinical application. The ability of persistence and survival is critical for tumor-associated antigen (TAA)-specific T cells to exert their antitumor effects 34 . T H 17 cells have survival advantages with stem cell properties 19, 36, 38, 40 . In line with this, we have found that polyfunctional T cells express EZH2 and have survival advantages in the cancer microenvironment. It is logical that the fraction of EZH2 + CD8 + T cells significantly and precisely predicts patient outcome. Our work indicates that polyfunctional CD8 + T cells are a precise prognostic factor for long-term cancer survival. Furthermore, EZH2 + CD8 + T cells may be a valuable marker for testing and screening clinical efficacy of immune therapy and vaccination. It is reasonable to assume that enhancing and/or maintaining EZH2 expression in T cells may be therapeutically meaningful in treating patients with cancer; however, EZH2 is highly expressed in various human cancer cells 27, 41 . Systemic epigenetic therapy, including EZH2 blockade, has been considered a powerful regimen to treating patients with cancer 42, 43 . Given the current overwhelming interest in epigenetic therapy, our data suggest that the potential effect of systemic epigenetic manipulation on T cell effector function should be taken into consideration. T cells and tumor cells may be differentially sensitive to epigenetic manipulation. A tumor-specific targeting approach or the use of minimal effective dosage would be a wise option in clinical exploration of epigenetic therapy. Furthermore, the combination of epigenetic therapy and immunotherapy may be sequentially used to enhance the therapeutic efficacy and minimize the potential side effect of certain epigenetic modifier(s). In the context of autoimmunity, T cells express high amounts of EZH2 in the microenvironment of ulcerative colitis, and it is assumed that inhibition of EZH2 expression or EZH2-associated signaling in T cells might be therapeutically beneficial.
In summary, we have demonstrated that EZH2 + CD8 + T cells constitute a functional effector T cell subset in human cancer; that EZH2 marks and controls effector T cell polyfunctionality and survival through an miRNA-EZH2-Notch signaling pathway; and that this pathway is regulated by glucose metabolism in the tumor microenvironment. Manipulation of this pathway may be useful in treating patients with cancer.
METHODS
Methods and any associated references are available in the online version of the paper. Table 5 ) were designed to detect promoter fragments near transcription start sites on NUMB and FBXW7 genes.
primers (Supplementary
Immunofluorescence and immunohistochemistry staining. We performed immunofluorescence staining in frozen tissue sections. The primary antibodies were mouse anti-human EZH2 (1:100, 612667, IgG1, BD Bioscience), rabbit anti-human CD3 (1:100, A0452, IgG, Dako), and TUNEL (S7165, Millipore). The secondary antibodies were goat anti-mouse IgG conjugated with Alexa Fluor 488 (1:2,000, A11001, Life Technologies) and goat anti-rabbit IgG conjugated with Alexa Fluor 568 (1:2,000, A11036, Life Technologies). The stained tissue sections were analyzed under a fluorescent microscope. Immunohistochemistry staining was performed in paraffin-fixed ovarian cancer tissues (Dako EnVision Double stain System, Dako). Paraffin-embedded TMA sections were deparaffinized and stained with rabbit anti-human EZH2 (1:200, 187395, Invitrogen) followed by Polymer-HRP and DAB Chromogen treatment. TMA sections were subsequently stained with mouse anti-human CD8 (1:50, M7103, Dako), followed by treatment with rabbit-mouse LINK, polymer-AP, permanent red chromogen and hematoxylin counterstaining. The TMA cores were quantified and analyzed for expression of EZH2 + and CD8 + T cells with an Aperio imaging system (Genetix). The specimens were digitalized with an automated platform (Aperio Technologies) and ScanScope XT and Spectrum Plus using TMA software version 9.1 scanning system. Cores were scored in high resolution at 40× magnification. Tissue sections were scored manually on a computer screen, and a mean score for duplicate cores from each individual was calculated. Any discrepancies were resolved by subsequent consultation with diagnostic pathologists. CD8 was localized in the cell membrane and cytoplasm and EZH2 was localized in the nuclei. CD8 and EZH2 were scored quantitatively (the numbers of positive cells). The tissues were divided into high and low CD8 + T cells (>7, <7) and EZH2 + CD8 + T cells (>2, <2), or by the percentage (>22%, <22%) of EZH2 + CD8 + T cells in CD8 + T cells on the basis of their median values per core ( Supplementary  Tables 1-4) . Staining with isotype antibody was used as negative control.
Statistical analysis.
Wilcoxon rank-sum tests were used to compare two independent groups, and for paired groups, Wilcoxon signed rank tests were used. Correlation coefficients (Spearman correlation (r) for ordinal data and Pearson correlation (r) for continuous data) and P values (null hypothesis is that r is in fact 0) were computed to measure the degree of association between biomarkers. Overall patient survival was defined as time from date of diagnosis to disease-related death. Disease-free interval was defined as time from date of diagnosis to disease progression or disease-related death. Data were censored at the last follow up for patients who were disease free or alive at the time of analysis. Survival functions were estimated by Kaplan-Meier methods. Cox's proportional hazards regression was performed to model survival as a function of the levels of CD8 + T cells, EZH2 + CD8 + T cells or the percentage of EZH2 + CD8 + T cells in CD8 + T cells (all classified as low and high on the basis of the median value), after adjusting for age, stage, histology, and debulking. We assessed the adequacy of the Cox regression model by graphical and numerical methods as described 26, 49, 50 . To estimate the performance of the levels of CD8 + T cells, EZH2 + CD8 + T cells and the percentage of EZH2 + CD8 + T cells for predicting patient survival, we used the time-dependent receiveroperating-characteristic (ROC) curve analysis 31 . The area under the ROC curve (AUC) was calculated to evaluate each marker's predictive accuracy. We used this analysis to evaluate and compare the predictive accuracy of the levels of CD8 + T cells, EZH2 + CD8 + T cells, and the percentage of EZH2 + CD8 + T cells for long-term survivals. All analyses were done using SAS 9.3 software. P < 0.05 was considered as significant.
